PHVS

Analyst Note: Pharvaris N.V. (PHVS)

Date: 2026-06-13 Subject: Structural Setup and Secular Thesis Review

1. Structural Readiness

Conservative Entry: $30.04 Current Price: $32.80 Extension: +9.2% vs. conservative entry Breakout Level: $30.04 (Conservative Entry)

Classification: CONFIRMED-ACTIVE

Volatility Context:

• ATR at Breakout: 4.4% (High) — Indicates strong structural quality and conviction at the time of the breakout.
• Current ATR: 4.9% (High) — Current volatility remains within the historical "sweet spot" (4–6%) for structural setups, suggesting manageable risk sizing without the elevated danger of extreme volatility (>8%).

2. The Thesis Layer

Primary Secular Thesis: Biotech & GLP-1 → Rare & Orphan (Tier Direct, High Confidence). Exposure Analysis: Pharvaris is a direct beneficiary of the "Rare & Orphan" sub-theme within the broader Biotech sector. The company is not a peripheral player; it is a primary developer of therapies for Hereditary Angioedema (HAE), a rare genetic disorder. The "Tier Direct" classification reflects that the company's entire value proposition is tied to the success of its specific asset class in this niche. There are no additional secular themes listed in the current membership data; the conviction rests entirely on the binary success of the HAE pipeline and the regulatory pathway for orphan drug designation and commercialization.

3. The Business

Company Overview: Pharvaris N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with operations in Switzerland and the United States. The company focuses on discovering and developing treatments for uncommon diseases, specifically targeting Hereditary Angioedema (HAE).

Business Model & Pipeline: The company operates on a clinical-stage development model, relying on the successful progression of its product candidates to late-stage trials and eventual regulatory approval.

• Primary Asset: Deucrictibant (PHA121), a small molecule bradykinin B2-receptor antagonist.
• Formulations: The company is developing two distinct formulations:
• Immediate-Release (IR) Capsule: Designed for on-demand treatment of acute HAE attacks.
• Extended-Release (XR) Tablet: Designed for prophylactic (preventative) treatment of HAE attacks.

Evidence as of 2026-06-13: According to the most recent primary filings (dated 2026-04-02), the company has released topline data demonstrating the efficacy and safety of deucrictibant for the on-demand treatment of HAE attacks across the RAPIDe-1, RAPIDe-2, and RAPIDe-3 studies. Furthermore, proof-of-concept and safety data for the prophylactic treatment (CHAPTER-1) have been released.

The company is currently managing three ongoing clinical studies:

• RAPIDe-2: An open-label extension study for the on-demand treatment of HAE attacks.
• CHAPTER-3: A pivotal Phase 3 study for the prophylactic treatment of HAE attacks.
• CHAPTER-4: An open-label extension study for the prophylactic treatment of HAE attacks.

Management has explicitly stated in filings that the company is "heavily dependent on the success of our product candidates deucrictibant immediate-release (IR) capsule and deucrictibant extended-release (XR) tablet, which are in late-stage development." The regulatory path has been cleared of previous hurdles; the FDA lifted clinical holds on the IND applications for both on-demand and prophylactic indications in June 2023 and January 2024, respectively, following the review of nonclinical rodent toxicology data.

4. Archetype and Conviction

Archetype: Growth Leader (Clinical-Stage Biotech) Pharvaris fits the "Growth Leader" archetype within the context of a clinical-stage biotech, specifically one approaching a potential inflection point from late-stage trials to commercialization. The company is not a deep value recovery play (as it has not yet generated revenue from the product) nor a cyclical recovery. It is a binary growth story driven by the execution of its Phase 3 program (CHAPTER-3) and the successful commercialization of its orphan drug candidates.

Valuation & Financial Context: The financial spine indicates a pre-revenue or early-revenue burn phase typical of late-stage biotechs.

The negative earnings reflect the heavy R&D expenditure required to complete the Phase 3 trials and prepare for potential launch. The "complete" coverage of the financial spine suggests the market has a clear view on the burn rate and capital requirements for the next 12-24 months.

• Forward Consensus EPS (FY1): -2.6445
• Forward Consensus EPS (FY2): -2.35445

Conviction Stack:

• Thesis Strength: High. The "Rare & Orphan" theme provides a clear regulatory and commercial pathway (orphan drug incentives).
• Evidence Quality: Strong. Multiple Phase 3 studies are active, and topline data has been released for earlier phases. The FDA has cleared previous clinical holds.
• Structural Quality: High. The ATR at breakout (4.4%) and current ATR (4.9%) indicate a healthy, active market with sufficient liquidity to support the setup without excessive noise.
• Rerating Potential: Significant. The market is currently pricing in the risk of clinical failure. Successful completion of the pivotal Phase 3 (CHAPTER-3) would represent a massive rerating event, moving the company from a speculative clinical-stage asset to a commercial entity.

5. Invalidations, Strengtheners, and Gaps

Invalidation Triggers:

• Fundamental: Failure of the pivotal Phase 3 (CHAPTER-3) study to meet primary endpoints, or a new FDA clinical hold issued due to safety concerns in the ongoing rodent or human studies.

Strengtheners:

• Structural: A sustained move higher with volume, extending the price further above the entry level while maintaining the ATR within the 4-6% range.
• Fundamental: Positive topline data readouts from the ongoing CHAPTER-3 or CHAPTER-4 studies, or the announcement of a partnership/licensing deal for the XR or IR formulations.

Evidence Gaps:

• Commercialization Timeline: While the filings confirm the *status* of the trials, there is no specific evidence in the provided data regarding the exact expected date of NDA submission or commercial launch.
• Capitalization Needs: The financial spine shows negative EPS, but there is no explicit evidence in the provided text regarding the company's current cash runway or the specific timing of potential dilutive capital raises required to fund the completion of Phase 3.
• Competitive Landscape: The evidence does not detail the competitive set or the specific market share assumptions used in the valuation models.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key risks: Binary outcome of Phase 3 clinical trial; potential for new FDA clinical hold; high cash burn rate requiring dilutive capital raises; lack of near-term revenue. Sizing hint: Position size should reflect the high ATR (4.9%) and the binary nature of the clinical catalyst; standard risk sizing for a confirmed biotech setup. Expected path: Management expects the completion of the pivotal Phase 3 study and subsequent regulatory filing; structural implication is a potential re-rating upon positive data readout or NDA acceptance. Expected horizon: 12 to 24 months, contingent on the completion of the CHAPTER-3 study and regulatory review.